Calithera Biosciences (NASDAQ:CALA) Coverage Initiated at StockNews.com
Calithera Biosciences (NASDAQ:CALA) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research report sent to investors on Friday. The firm issued a hold rating on the biotechnology company's stock.
證券新聞網開始對股票的報導 卡利瑟拉生物科學 (納斯達克:卡拉 — 獲得評級) 在上週五發送給投資者的研究報告中。該公司對生物技術公司的股票發出了持有評級。
A number of other equities research analysts also recently weighed in on CALA. SVB Leerink downgraded Calithera Biosciences from an outperform rating to a market perform rating in a research report on Tuesday, November 15th. LADENBURG THALM/SH SH downgraded Calithera Biosciences from a buy rating to a neutral rating in a report on Tuesday, November 15th.
一些其他股票研究分析師最近也稱重 CALA。SVB Leerink 降級卡里瑟拉生物科學從一個超越評級到市場上週二的研究報告進行評級, 11 月 15 日.拉登堡 THAM/SH SH 在星期二的一份報告中，將卡里瑟拉生物科學從買入評級降級為中性評級，11 月 15 日。
Calithera Biosciences Stock Up 17.6 %
卡利瑟拉生物科學股票上漲 17.6%
CALA stock opened at $0.06 on Friday. The company has a market cap of $292,200.00, a P/E ratio of 0.00 and a beta of 1.22. Calithera Biosciences has a twelve month low of $0.05 and a twelve month high of $13.38. The business has a fifty day moving average of $0.84 and a 200-day moving average of $2.09.
卡拉股票上週五以 0.06 美元開盤。該公司的市值為 292,200 美元，市盈率為 0.00 美元，貝塔值為 1.22。卡利塞拉生物科學有十二個月低點 0.05 美元和十二個月高點 13.38 美元。該業務的五十天移動平均線為 0.84 美元，200 天移動平均線為 2.09 美元。
Insider Activity at Calithera Biosciences
卡利塞拉生物科學的內幕活動
In related news, Director Deepika Pakianathan sold 121,333 shares of the company's stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $0.39, for a total value of $47,319.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.60% of the stock is currently owned by corporate insiders.
在相關消息中，董事 Deepika 巴基斯坦人在 1 月 27 日（星期五）的一項交易中出售了該公司股票的 121,333 股。該股票以 0.39 美元的平均價格出售，總價值為 47,319.87 美元。該交易已在向證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 這個鏈接。6.60％ 的股票目前由企業內部人士擁有。
Institutional Investors Weigh In On Calithera Biosciences
機構投資者權衡卡利塞拉生物科學
Several large investors have recently modified their holdings of the business. TSP Capital Management Group LLC increased its holdings in shares of Calithera Biosciences by 18.0% in the third quarter. TSP Capital Management Group LLC now owns 62,900 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 9,605 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Calithera Biosciences by 13.8% during the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company's stock worth $337,000 after buying an additional 13,855 shares during the period. Vanguard Group Inc. boosted its position in shares of Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock worth $415,000 after buying an additional 26,800 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock worth $50,000 after buying an additional 72,865 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Calithera Biosciences during the first quarter worth about $404,000. 33.73% of the stock is currently owned by institutional investors.
一些大型投資者最近修改了他們對業務的持有量。TSP 資本管理集團有限責任公司在第三季度增加了其在卡利塞拉生物科學股份的持有量 18.0%。TSP 資本管理集團有限責任公司現在擁有該生物技術公司股票的 62,900 股，價值 $185,000 在上個季度獲得了 9,605 股之後。文藝復興技術有限責任公司在第三季度提高了其在卡利塞拉生物科學股份的地位 13.8%.文藝復興技術有限責任公司現在擁有 114,555 股價值 337,000 美元的生物技術公司股票的股票在此期間額外購買 13,855 股後。先鋒集團公司在第三季度將其在卡利塞拉生物科學的股份地位提高了 23.4％。領航集團股份有限公司現時擁有該生物科技公司股票的 141,217 股股票，價值 415,000 美元，並於期內額外購入 26,800 股股份。高盛集團公司在第一季度提高了其在卡利塞拉生物科學股份的地位 143.2％。期內，高盛集團股份有限公司現在擁有該生物科技公司股票價值 50,000 美元的 123,739 股股份。最後，阿麗斯卡投資集團 L.P. 在第一季度收購了卡利瑟拉生物科學股份的新頭寸，價值約為 404,000 美元。33.73％ 的股票目前由機構投資者擁有。
About Calithera Biosciences
關於卡利瑟拉生物科學
(Get Rating)
(取得評分)
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.
Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Go Where the Money Is. Here's 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
- 獲取有關卡利瑟拉生物科學研究報告的免費副本
- 去錢所在的地方。這是 3 個要購買的頂級銀行股息股票
- 馬倫汽車股票的另一種催化劑
- 太陽能技術服務；Nextracker 應該在您的雷達上
- 隨著對鋰的需求飆升，美國鋰是安全的賭注嗎
- 高木物業，優質房地產折扣
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。